Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jerome Watson

Physical Medicine & Rehabilitation Statesville, NC Medical Doctor

NPI 1336144138 CMS profile 287431

293 Old Mocksville Road, Statesville, NC 28625

Open in the dashboard

General payments

$15,275

915 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jerome Watson of Statesville, NC is reported in the CMS Open Payments database as having received $15,275 across 915 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,814 98
2024 General $2,519 139
2023 General $2,717 148
2022 General $2,518 166
2021 General $2,295 139
2020 General $1,656 103
2019 General $1,754 122

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerome Watson
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Jerome Watson were reported at $1,814. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Jerome Watson Physical Medicine & Rehabilitation median Middle half National median
2019 $1,754 $133 $45–$390 $163
2020 $1,656 $88 $29–$272 $114
2021 $2,295 $116 $33–$360 $132
2022 $2,518 $123 $40–$378 $149
2023 $2,717 $131 $43–$396 $160
2024 $2,519 $141 $45–$409 $164
2025 $1,814 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,912 179 payments
  2. Novartis Pharmaceuticals Corporation $1,680 110 payments
  3. AbbVie, Inc. $1,656 80 payments
  4. Janssen Biotech, Inc. $1,341 86 payments
  5. UCB, Inc. $925 77 payments
  6. ANI Pharmaceuticals, Inc. $869 59 payments
  7. Radius Health, Inc. $646 31 payments
  8. Collegium Pharmaceutical, Inc. $457 22 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $444 27 payments
  10. Pfizer Inc. $385 34 payments
  11. Other $3,961 210 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,246 913 payments
  2. Education $16 1 payment
  3. Entertainment $13 1 payment
Products named General payments · program years 2019–2025
  1. Prolia $967 55 payments
  2. COSENTYX Dermatology $963 64 payments
  3. TREMFYA $826 46 payments
  4. Otezla $800 47 payments
  5. Cimzia $791 70 payments
  6. RINVOQ $736 36 payments
  7. COSENTYX Immunology $717 46 payments
  8. SIMPONI ARIA $659 48 payments
  9. Enbrel $653 43 payments
  10. EVENITY $511 32 payments
  11. Other $11,161 639 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

4,318

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$233,687

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

36%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 50 $30,063
Hysingla Er Hydrocodone Bitartrate Brand 28 $22,802
Linzess Linaclotide Brand 31 $21,957
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 591 $19,139
Oxymorphone Hcl Er Oxymorphone Hcl Brand 37 $18,609
Oxycontin Oxycodone Hcl Brand 14 $17,640
Oxycodone Hcl Generic 713 $15,090
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 382 $12,899
Morphine Sulfate Er Morphine Sulfate Brand 243 $8,577
Buprenorphine Generic 27 $8,021

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$366,285

Of which drugs: $5,994

Medicare patients

327

Average age 68

Services billed

7,715

207 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Depression 38%
COPD 32%
Chronic kidney disease 29%
Ischemic heart disease 25%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 46 298 $219
Injection, ketorolac tromethamine, per 15 mg J1885 Office 50 289 $149

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$338 — —
COSENTYX
$318 — —
PURIFIED CORTROPHIN GEL
$287 — —
OFEV
$172 — —
Tymlos
$154 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

915 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record